Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
CONTEXT: Levothyroxine monotherapy is the treatment of choice for hypothyroid patients because peripheral T4 to T3 conversion is believed to account for the overall tissue requirement for thyroid hormones. However, there are indirect evidences that this may not be the case in all patients. OBJECTIVE: To evaluate in a large series of athyreotic patients whether levothyroxine monotherapy can normalize serum thyroid hormones and thyroid-pituitary feedback. DESIGN: Retrospective study. SETTING: Academic hospital. PATIENTS: 1,811 athyreotic patients with normal TSH levels under levothyroxine monotherapy and 3,875 euthyroid controls. MEASUREMENTS: TSH, FT4 and FT3 concentrations by immunoassays. RESULTS: FT4 levels were significantly higher and FT3 levels were significantly lower (p<0.001 in both cases) in levothyroxine-treated athyreotic patients than in matched euthyroid controls. Among the levothyroxine-treated patients 15.2% had lower serum FT3 and 7.2% had higher serum FT4 compared to euthyroid controls. A wide range of FT3/FT4 ratios indicated a major heterogeneity in the peripheral T3 production capacity in different individuals. The correlation between thyroid hormones and serum TSH levels indicated an abnormal feedback mechanism in levothyroxine-treated patients. CONCLUSIONS: Athyreotic patients have a highly heterogeneous T3 production capacity from orally administered levothyroxine. More than 20% of these patients, despite normal TSH levels, do not maintain FT3 or FT4 values in the reference range, reflecting the inadequacy of peripheral deiodination to compensate for the absent T3 secretion. The long-term effects of chronic tissue exposure to abnormal T3/T4 ratio are unknown but a sensitive marker of target organ response to thyroid hormones (serum TSH) suggests that this condition causes an abnormal pituitary response. A more physiological treatment than levothyroxine monotherapy may be required in some hypothyroid patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These changes are an increase in T4 or free T4 (fT4) levels, an increase in fT4/T3 ratios, associated with a decline in T3 or free T3 (fT3) levels.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, in children and adults with an intact HPT axis, fT3 levels do not correlate with TSH levels (and in children they show a positive rather than the negative correlation seen with fT4) (11,87).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, low FT3 and an increased FT4/FT3 ratio after thyroidectomy has been reported in about 15% of a large unselected population (102).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lean body mass is not the only variable to estimate the therapeutic post-thyroidectomy LT4 dose, owing to the disappearance of thyroidal contribution to circulating T3 (102).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, Levothyroxine affects the T3:T4 ratio and individuals on levothyroxine have relatively low FT3: FT4 ratios [110].”
From Age-related variation in thyroid function – a narrative review highlighting important implications for research and clinical practice (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853 · cited 1×
“he insufficient T3 peripheral production cannot be appropriately corrected by increasing levothyroxine dose because the inhibitory effect of elevated T4 on type II deiodinase [27,28] will end up increasing the imbalance of the circulating FT3/FT4 ratio (Figure 3).”
Deiodinases: implications of the local control of thyroid hormone action
Bianco, A. C., & Kim, B. W. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29812 · Cited by 845
Selenium, the Thyroid, and the Endocrine System
Köhrle, J., Jakob, F., Contempré, B., & Dumont, J. E. (2005) · Endocrine Reviews · doi:10.1210/er.2001-0034 · Cited by 529 · cited 1×
“function [23,24,25] and also abnormal thyroid hormone metabolism independent from deiodination [26].”
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“Their condition may ameliorate under a combined T4-T3 treatment [1,18,19,20].”
Zulewski, H., Müller, B., Exer, P., Miserez, A. R., & Staub, J.-J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3810 · Cited by 338 · cited 1×
“secreted TSH may not reflect what happens in other target tissues and, therefore, in some instances serum TSH may not be an appropriate indicator of peripheral tissue euthyroidism [7,8,9].”
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327 · cited 1×
“Their condition may ameliorate under a combined T4-T3 treatment [1,18,19,20].”
Wekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299 · cited 1×
“It should be underlined, however, that no long-term study is available to assess that the abnormal circulating thyroid hormone ratio has no adverse effect and that even short-term studies indicate that some hypothyroid patients do not reach a condition of well-being and emotional satisfaction under levothyroxine monot…”
Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296 · cited 2×
“general well-being under levothyroxine monotherapy and (iii) that in many studies a short period of T4-T3 combination therapy has not caused a significant improvement in a variety of symptoms, the conclusion has been drown that levothyroxine monotherapy must be the standard treatment for all hypothyroid patients [16].”
Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287 · cited 3×
“The major source of T3 within peripheral tissues comes from the circulating T3 pool and the variable portion coming from locally deiodinated T4 within each tissue might be not adequate according to animal experiments [5].”
Cited by
Items 101–200 of 307
Da Conceição, R. R., Fernandes, G. W., Fonseca, T. L., Bocco, B. M. L. C., & Bianco, A. C. (2018) · Thyroid · doi:10.1089/thy.2018.0205 · Cited by 23
“It is also known that normalization of serum TSH with LT4 monotherapy to hypothyroid patients results in 5–10% lower serum T3 (7,13).”
Bjerkreim, B. A., Hammerstad, S. S., Gulseth, H. L., Berg, T. J., Omdal, L. J., Lee-Ødegård, S., & Eriksen, E. F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816566 · Cited by 24
Sohn, S. Y., Joung, J. Y., Cho, Y. Y., Park, S. M., Jin, S., Chung, J. H., & Kim, S. W. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.3.343 · Cited by 25
Functional and Symptomatic Individuality in the Response to Levothyroxine Treatment
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00664 · Cited by 22
“, with persistently low FT3 concentrations despite normalized TSH (77), appears feasible, but was not tested in this study and awaits further proof.”
BackgroundT4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
Wiersinga, W. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.501 · Cited by 21
“2% of patients have FT3 levels below the lower normal limit [45].”
BackgroundCardiovascular Outcomes in Thyroid Cancer Patients Treated With Thyroidectomy: A Meta-Analysis
Lee, E. K., Ahn, H. Y., Ku, E. J., Yoo, W. S., Lee, Y. K., Nam, K., Chai, Y. J., Moon, S., & Jung, Y. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab576 · Cited by 32
Brigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 23
Combination Thyroid Hormone Replacement; Knowns and Unknowns
Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C., & Okosieme, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00706 · Cited by 21
“LT4 monotherapy results in individuals having relatively lower FT3 and higher FT4 levels than individuals with an intact, undisturbed, hypothalamopituitary-thyroid (HPT) axis (13), but the clinical relevance of this finding is controversial (14).”
BackgroundDumitrescu, A. M., Hanlon, E. C., Arosemena, M., Duchon, O., Ettleson, M., Giurcanu, M., & Bianco, A. C. (2022) · Thyroid · doi:10.1089/thy.2021.0304 · Cited by 20
“First noticed around 1974 (6), subsequent studies revealed that LT4-treated patients maintain * 10% lower serum T3 levels compared with euthyroid individuals with similar TSH levels (7,8).”
Gullo, D., Latina, A., Frasca, F., Squatrito, S., Belfiore, A., & Vigneri, R. (2017) · Clinical Endocrinology · doi:10.1111/cen.13351 · Cited by 20
Self-citationRomero-Gómez, B., Guerrero-Alonso, P., Carmona‐Torres, J. M., Pozuelo‐Carrascosa, D. P., Laredo‐Aguilera, J. A., & Cobo‐Cuenca, A. I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123864 · Cited by 25
An Italian Survey of Compliance With Major Guidelines for L-Thyroxine of Primary Hypothyroidism
Vezzani, S., Giannetta, E., Altieri, B., Barbonetti, A., Bellastella, G., Certo, R., Cignarelli, A., Cinti, F., D’Andrea, S., Dalmazi, G. D., et al. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0159 · Cited by 24
Derakhshan, A., Männistö, T. I., Chen, L., Osinga, J. A. J., Ashoor, G., Lu, X., Bliddal, S., Tao, F., Brown, S. J., Vaidya, B., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad631 · Cited by 20
CD5L Constitutes a Novel Biomarker for Integrated Hepatic Thyroid Hormone Action
Nock, S., Johann, K., Harder, L., Wirth, E. K., Renko, K., Hoefig, C. S., Kracke, V., Hackler, J., Engelmann, B., Rauner, M., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0635 · Cited by 19
“This indicates an incomplete substitution not captured by the conventional diagnostic approach (7) and has resulted in a highly controversial discussion, whether L-triiodothyronine (LT3) should be added during the supplementation therapy, although a clear bene-ficial effect has yet to be…”
Monzani, M. L., Piccinini, F., Boselli, G., Corleto, R., Margiotta, G., Peeters, R. P., Simoni, M., & Brigante, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01903-6 · Cited by 22
Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism
Park, E., Jung, J., Araki, O., Tsunekawa, K., Park, S. Y., Kim, J., Murakami, M., Jeong, S., & Lee, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-28480-0 · Cited by 19
Santini, F., Ceccarini, G., Pelosini, C., Giannetti, M., Ricco, I., Querci, G., Grossi, E., Saponati, G., & Vitti, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00826 · Cited by 17
Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients
Ito, M., Miyauchi, A., Hisakado, M., Yoshioka, W., Kudo, T., Nishihara, E., Kihara, M., Ito, Y., Miya, A., Fukata, S., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0094 · Cited by 17
Žarković, M., Wiersinga, W. M., Perros, P., Bartalena, L., Donati, S., Okosieme, O. E., Morris, D. S., Fichter, N., Lareida, J., Daumerie, C., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01320-7 · Cited by 17
Combination Therapy for Hypothyroidism: Rationale, Therapeutic Goals, and Design
Madan, R., & Celi, F. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00371 · Cited by 18
“Of interest, while LT4 therapy is extremely effective in normalizing TSH, it does not appear to completely normalize the serum concentrations of T4 and T3, since the ratio T4:T3 is skewed toward an increase of T4, while T3 levels are normal to low (5).”
BackgroundAzizi, F., Abdi, H., Cheraghi, L., & Amouzegar, A. (2021) · Thyroid · doi:10.1089/thy.2020.0433 · Cited by 21
“However, RAI treatment induces hypothyroidism in majority of patients over time and levothyroxine replacement may be accompanied by difficulties, in particular in the elderly (1,30).”
Clinical significance of type 2 iodothyronine deiodinase polymorphism
Maino, F., Cantara, S., Forleo, R., Pilli, T., & Castagna, M. G. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1523714 · Cited by 17
Oto, Y., Muroya, K., Hanakawa, J., Asakura, Y., & Adachi, M. (2015) · Thyroid Research · doi:10.1186/s13044-015-0023-5 · Cited by 16
“Whereas FT3/FT4 ratio has been reported to be constant in healthy adult individuals [3], the consistency of this ratio has not yet been clearly determined in the pediatric population.”
BackgroundInfluentialPostradioiodine Graves' management: The PRAGMA study
Perros, P., Basu, A., Boelaert, K., Dayan, C., Vaidya, B., Williams, G. R., Lazarus, J. H., Hickey, J., Drake, W. M., Crown, A., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14719 · Cited by 16
Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism
Penna, G., Salas-Lucia, F., Ribeiro, M. O., & Bianco, A. C. (2023) · Endocrine · doi:10.1007/s12020-023-03528-y · Cited by 20
“What is more important is that ∼ 15% of the LT4-treated patients exhibit an absolute de fi ciency of T3, with circulating values below the normal reference range despite normalization of serum TSH [21, 22].”
Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil
Penna, G. C., Bensenor, I. M., Bianco, A. C., & Ettleson, M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae139 · Cited by 16
Hypothyroidism and Thyroiditis
Brent, G. A., & Weetman, A. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00013-7 · Cited by 24
Systemic Thyroid Hormone Status in Treated Graves’ Disease
Azizi, F., Amouzegar, A., Tohidi, M., Hedayati, M., Cheraghi, L., & Mehrabi, Y. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.95385 · Cited by 19
“Previous studies have also shown the same results in the LT4 monotherapy settings, as compared to normal controls (2-4).”
BackgroundResultIdentification of Resistance to Exogenous Thyroxine in Humans
Lacámara, N., Beatriz Lecumberri, S., Barquiel, B., Escribano, A., Casado, I. G., Álvarez‐Escolá, C., Blanquer, F. A., Morales, F., Alfayate, R., Bernal-Soriano, M. C., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0825 · Cited by 17
Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review
Razvi, S., Mrabeti, S., & Luster, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0205 · Cited by 15
Ito, M., Kawasaki, M., Danno, H., Kohsaka, K., Nakamura, T., Hisakado, M., Yoshioka, W., Kasahara, T., Kudo, T., Nishihara, E., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0135 · Cited by 18
Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia
Prete, A., Matrone, A., Gambale, C., Bottici, V., Cappagli, V., Romei, C., Torregrossa, L., Valerio, L., Minaldi, E., Campopiano, M. C., et al. (2021) · Cancers · doi:10.3390/cancers13215554 · Cited by 16
“In addition, biochemical features in athyreotic patients seem to be different from those in euthyroid ones, as demonstrated by Gullo and colleagues, who showed that athyreotic patients treated with LT4 had higher fT4 and lower fT3 levels than euthyroid control and about one third of them had lower than reference fT4/f…”
ResultBiondi, B., Pucci, M., Pontieri, G., Formisano, P., & Esposito, R. (2023) · Thyroid · doi:10.1089/thy.2023.0135 · Cited by 15
“42 It is uncertain whether replacement therapy with LT4 alone is able to completely normalize the cardiovascular function in hypothyroid patients without a residual thyroid function because no data are currently available on the long-term effects of this treatment.”
Molewijk, E., Fliers, E., Dreijerink, K. M. A., van Dooren, A. A., & Heerdink, E. R. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100330 · Cited by 31
“In our study, 52 % of patients had low FT3 concentrations, which is much more than the 15 % reported by Gullo in athyreotic LT4-treated patients [43].”
Jonklaas, J., Sathasivam, A., Wang, H., Finigan, D., Soldin, O. P., Burman, K. D., & Soldin, S. J. (2014) · Endocrine Practice · doi:10.4158/ep13453.or · Cited by 15
“LT4-treated patients have been documented to have higher T4 levels than euthyroid patients not receiving treatment and also frequently have lower than normal T3 levels (27-30).”
BackgroundHirata, Y., Fukuoka, H., Iguchi, G., Iwahashi, Y., Fujita, Y., Hari, Y., Iga, M., Nakajima, S., Nishimoto, Y., Mukai, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0130 · Cited by 14
Increased fT4 concentrations in patients using levothyroxine without complete suppression of TSH
Jansen, H. I., Bult, M., Bisschop, P. H. L. T., Boelen, A., Heijboer, A. C., & Hillebrand, J. J. (2023) · Endocrine Connections · doi:10.1530/ec-22-0538 · Cited by 14
Berghoff, A. S., Wippel, C., Starzer, A. M., Ballarini, N. M., Wolpert, F., Bergen, E. S., Wolf, P. S., Steindl, A., Widhalm, G., Gatterbauer, B., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.011 · Cited by 14
“Patients treated with levothyroxine (T4) were shown to not achieve serum levels of T3 within the NR owing to inadequate conversion, which results in a high T4/T3 serum ratio [21].”
BackgroundLevothyroxine treatment and cholesterol in hypothyroidism
Bianco, A. C., & Taylor, P. N. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0323-2 · Cited by 17
Hoermann, R., Midgley, J. E. M., Dietrich, J. W., & Larisch, R. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817716401 · Cited by 14
Biondi, B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02302 · Cited by 17
Mele, C., Tagliaferri, A., Pagano, L., Soranna, D., Scacchi, M., Aimaretti, G., Biondi, B., & Marzullo, P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00773 · Cited by 15
Hypothyroidism, comorbidity and health-related quality of life: a population-based study
Wouters, H. J. C. M., Wolffenbuttel, B. H. R., Kobold, A. C. M., Links, T. P., Huls, G. A., & van der Klauw, M. M. (2023) · Endocrine Connections · doi:10.1530/ec-23-0266 · Cited by 17
“It has been shown that in patients treated with levothyroxine monotherapy with normal TSH levels, FT4 levels were significantly higher and FT3 significantly lower than in euthyroid control subjects (4, 5).”
BackgroundIto, M., Takahashi, S., Okazaki‐Hada, M., Minakata, M., Kohsaka, K., Nakamura, T., Kasahara, T., Kudo, T., Nishihara, E., Fukata, S., et al. (2022) · Thyroid Research · doi:10.1186/s13044-022-00127-3 · Cited by 13
“They concluded that FT4 and FT3 concentrations are not necessarily within reference ranges in patients with normal TSH concentrations [3].”
BackgroundJonklaas, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934003 · Cited by 13
“In addition, ratios of FT4 to T3 are higher in the treated state (4), while FT3 to FT4 ratios are lower (5, 6) (see Table 1).”
BackgroundHaddow, J. E., Neveux, L. M., Palomaki, G. E., Lambert-Messerlian, G. M., Malone, F. D., & D’Alton, M. E. (2015) · Thyroid · doi:10.1089/thy.2015.0085 · Cited by 12
Variants in MCT10 protein do not affect FT3 levels in athyreotic patients
Cantara, S., Ricci, C., Maino, F., Marzocchi, C., Pacini, F., & Castagna, M. G. (2019) · Endocrine · doi:10.1007/s12020-019-02001-z · Cited by 12
Hypothyroidism and Myxedema Coma
Wiersinga, W. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00088-3 · Cited by 16
Variable transduction of thyroid hormone signaling in structures of the mouse brain
Sinkó, R., Salas-Lucia, F., Mohácsik, P., Halmos, E., Wittmann, G., Egri, P., Bocco, B. M. L. C., Batistuzzo, A., Fonseca, T. L., Fekete, C., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2415970122 · Cited by 13
Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies
Rossi, L., Paternoster, M., Cammarata, M., Bakkar, S. Y., & Miccoli, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1582734 · Cited by 16
Serum microRNA profiles in athyroid patients on and off levothyroxine therapy
Massolt, E. T., Chaker, L., Visser, T. J., Gillis, A., Dorssers, L. C. J., Beukhof, C. M., Kam, B. L. R., Franssen, G. J. H., Brigante, G., van Ginhoven, T. M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194259 · Cited by 13
LT4 and Slow Release T3 Combination: Optimum Therapy for Hypothyroidism?
Azizi, F., Amouzegar, A., Mehran, L., & Abdi, H. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.100870 · Cited by 14
“documented that LT4 monotherapy could not guarantee euthyroidism in athyreotic patients, as these patients had highly heterogeneous T3 production capacity during LT4 monotherapy, abnormal T3:T4 ratios were seen in > 20% of them (15).”
BackgroundInfluentialRutigliano, G., Bertolini, A., Grittani, N., Frascarelli, S., Carnicelli, V., Ippolito, C., Moscato, S., Mattii, L., Kusmic, C., Saba, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813845 · Cited by 12
“Additionally, generation of triiodothyronine (T3) from thyroxine (T4) by deiodinases may not be equivalent to thyroidal secretion of T3 [21].”
BackgroundZhang, H., Tong, W., Zeng, W., Luo, H., Zhang, L., Feng, J., Xiao, Y., & Wang, G. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627787 · Cited by 19
Razvi, S., Ryan, V., Ingoe, L. E., Pearce, S. H. S., & Wilkes, S. (2019) · European Thyroid Journal · doi:10.1159/000504047 · Cited by 16
Filipchuk, M., Gassmann, J., Zamparella, T. C., Tibaldo, M. C., Carpinella, M., Tagliavini, P. S., Scarnato, P., Goicochea, M. T., Bruera, O. C., Magris, D. M. C., et al. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05424-7 · Cited by 11
Oteri, V., Volpe, S., Lopes, M., Sceusa, G., Tumminia, A., Belfiore, A., Frasca, F., & Gullo, D. (2024) · Endocrine · doi:10.1007/s12020-024-04016-7 · Cited by 9
“For example, in athyreotic patients L-T4 monotherapy may not provide euthyroidism due to variability in T3 production: indeed, more than 20% of patients in the study by Gullo et al. [8] exhibited abnormal T3:T4 ratios.”
Self-citationTriiodothyronine alongside levothyroxine in the management of hypothyroidism?
Gottwald-Hostalek, U., & Kahaly, G. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1984219 · Cited by 9
Phan, G. Q., Yavuz, S., Stamatouli, A. M., Madan, R., Chen, S., Grover, A. C., Nilubol, N., Bedoya, P., Trankle, C. R., Markley, R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1522753 · Cited by 9
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100219 · Cited by 12
Heim, M., Nixon, I. J., Emmerson, E., & Callanan, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.997288 · Cited by 13
“physiological free T3:T4 ratio, despite presenting with TSH serum level within the normal range (133, 134).”
BackgroundAdult Thyroid Outcomes of Congenital Hypothyroidism
Sugisawa, C., Narumi, S., Tanase‐Nakao, K., Hoshiyama, A., Suzuki, N., Ohye, H., Fukushita, M., Matsumoto, M., Yoshihara, A., Watanabe, N., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0481 · Cited by 11
Larsen, C. B., Winther, K. H., Cramon, P. K., Rasmussen, Å. K., Feldt‐Rasmussen, U., Grøenvold, M., Bjørner, J. B., Hegedűs, L. D., Watt, T., & Bonnema, S. J. (2023) · Thyroid Research · doi:10.1186/s13044-023-00178-0 · Cited by 12
“Gullo et al. reported that approximately 15% of patients on LT4 treatment had a plasma T3 below the normal reference range [19].”
BackgroundBarr, C. E., Njoku, K., Hotchkies, L., Ryan, N. A. J., Wan, Y.-L. L., Davies, D. A., Razvi, S., & Crosbie, E. J. (2021) · Cancers · doi:10.3390/cancers13215444 · Cited by 10
“It has been shown that patients treated with levothyroxine may not achieve the required serum levels of T3, suggesting inadequate peripheral conversion leading to an increased T4:T3 ratio that, in a number of patients, never reaches the level required of those who are euthyroid despite a normal serum TSH, and this is…”
BackgroundStrich, D., Chay, C., Karavani, G., Edri, S., & Gillis, D. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0751-0498 · Cited by 9
Treatment of Hypothyroidism: Possibilities on the Horizon
Jonklaas, J., Burman, K. D., & Bianco, A. C. (2013) · Thyroid · doi:10.1089/thy.2013.0171 · Cited by 10
“Some (8,9), but not all (10), studies suggest that serum triiodothyronine (T3) may be lower in levothyroxine-replaced patients than in the euthyroid population.”
Takahashi, S., Ito, M., Masaki, Y., Okazaki‐Hada, M., Minakata, M., Kohsaka, K., Nakamura, T., Kasahara, T., Kudo, T., Nishihara, E., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0542 · Cited by 10
“jp after radioiodine treatment for Graves’ disease [2-5].”
BackgroundMoli, R. L., Malandrino, P., Russo, M., Tumino, D., Piticchio, T., Naselli, A., Rapicavoli, V., Belfiore, A., & Frasca, F. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.406 · Cited by 9
Self-citationZamar, A., Lulsegged, A., & Kouimtsidis, C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.976544 · Cited by 8
“A study published in 2011 looking at 1,811 athyreotic patients with normal TSH levels taking levothyroxine monotherapy and 3,875 euthyroid controls showed more than 20% of the group taking Levothyroxine had significantly higher free T4 and lower free T3 levels compared to euthyroid controls, despite having normal TSH…”
BackgroundRole of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism
Jonklaas, J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.003 · Cited by 10
Pappy, A. L., Oyesiku, N. M., & Ioachimescu, A. G. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616661834 · Cited by 8
Korwutthikulrangsri, M., Dosiou, C., Dumitrescu, A. M., & Refetoff, S. (2019) · European Thyroid Journal · doi:10.1159/000503860 · Cited by 7
Commentary on: Guidelines for the Treatment of Hypothyroidism
Kopp, P. A. (2014) · Thyroid · doi:10.1089/thy.2014.2412 · Cited by 7
“However, a subset of patients remains symptomatic despite the normalization of their thyroid hormone levels (23,24).”
Premawardhana, L. D., Taylor, P. N., Okosieme, O. E., Adlan, M. A., Obuobie, E. K., & Dayan, C. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1282608 · Cited by 6
Bakos, B., Solymosi, T., Szili, B., Vincze, Á., Mészáros, S., Stempler, M., Armos, R., Kiss, A., Bakos, A., Szücs, N., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01962-9 · Cited by 8
“Decreased free T3 (FT3) levels have been observed in individuals treated with thyroxine [6], and symptomatic improvement has been reported with normalization of FT3, even in the context of normal TSH levels [7].”
Лікування гіпотиреозу згідно із сучасними клінічними настановами
Pashkovska, N. V. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.6.78.2016.81860 · Cited by 12
Jensen, C. Z., Isaksen, J. L., Ahlberg, G., OLESEN, M. S., Nygaard, B., Ellervik, C., & Kanters, J. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad556 · Cited by 8
Clinical challenges in thyroid disease: Time for a new approach?
Juby, A. G., Hanly, M. G., & Lukaczer, D. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.02.001 · Cited by 8
Levothyroxine use and the risk of colorectal cancer: a large population-based case–control study
Kuiper, J. G., Fenneman, A. C., van der Spek, A. H., Rampanelli, E., Nieuwdorp, M., van Herk‐Sukel, M. P. P., Lemmens, V. E. P. P., Kuipers, E. J., Herings, R. M. C., & Fliers, E. (2021) · Endocrine Connections · doi:10.1530/ec-21-0463 · Cited by 8
“(3) The use of levothyroxine, which is a synthetic form of T4, lowers the serum (free)T3:(free)T4 ratio.(18) However, circulating TH concentrations do not necessarily reflect intracellular TH bioavailability.”
BackgroundShahrivar, F. F., Badavi, M., Dianat, M., Mard, S. A., Ahangarpour, A., & Samarbafzadeh, A. (2016) · Gene · doi:10.1016/j.gene.2016.09.025 · Cited by 7
“Besides, levothyroxine monotherapy in some hypothyroid patients is insufficient to achieve a normal range of serum TSH hormone (Gullo et al., 2011).”
BackgroundEfficacy of Ayurvedic Interventions in Hypothyroidism
Dixit, A. K., Sarkar, M., Nair, P. G., Puia, L., Bora, M., Gaidhani, S. N., & Hazra, J. (2019) · Journal of Research in Ayurvedic Sciences · doi:10.5005/jras-10064-0090 · Cited by 6
Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe
Othman, R. A., Myrie, S. B., Mymin, D., Roullet, J., DeBarber, A. E., Steiner, R. D., & Jones, P. J. H. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.05.049 · Cited by 6
“37).(26) All patients had high plasma and RBC cholestanol and sitostanol levels.”
Jonklaas, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-72102-6_19 · Cited by 6
Yuan, Q., Li, C., Zhou, R., Hou, J., Li, J., & Wu, G. (2025) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1177/19160216251348423 · Cited by 5
Piticchio, T., Luongo, C., Trimboli, P., Salvatore, D., & Frasca, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02480-6 · Cited by 6
“To date, this issue has been studied mainly by focus - sing on the lower part of the HPT axis through the obser - vation of TH levels and effects [10, 21 – 27].”
Self-citationWeng, J., Wei, J., Li, M., Ning, L., Liu, F., Wei, Y., Xiong, W., Zhang, B., Lu, J., Jiang, H., et al. (2022) · Head & Neck · doi:10.1002/hed.27006 · Cited by 5
“The usual standard thyroid replacement therapy is T4, which must be converted to T3 in tissues by iodoadenine deiodinase to gain biological activity.27 In patients treated with T4, the serum T4/T3 ratio is high due to inadequate conversion of levothyroxine (T4), which does not reach the normal range of serum levels of…”
BackgroundThe unique signature of tyrosine kinase inhibitor-induced hypothyroidism
Porcelli, T., Stefano, M. A. D., Luongo, C., Schlumberger, M. J., & Salvatore, D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00193-7 · Cited by 6
Penna, G., Guimarães, R. O., Benseñor, I. M., Ettleson, M. D., Pires, M. C., & Bianco, A. C. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.023 · Cited by 4
Heald, A. H., Premawardhana, L. D. K. E., Taylor, P. N., Bahl, S., Okosieme, O. E., Fryer, A. A., Bianco, A. C., Dayan, C. M., & Stedman, M. (2025) · Clinical Endocrinology · doi:10.1111/cen.70074 · Cited by 4
Funkquist, A., Wandt, B., Blennow, K., Zetterberg, H., Svensson, J., Bjellerup, P., Freund‐Levi, Y., & Sjöberg, S. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13272 · Cited by 4
“This could possibly explain why serum(s) T3/T4 ratio, both in terms of total and free fractions, of the hormones are lower during treatment as compared with healthy controls, since DIO2 activity is downregulated by the excess T4 concentration.(19,20) These lower T3/T4 ratios have been inversely associated with physica…”
Metabolic Consequences of Thyroidectomy and Patient-Centered Management
Wang, K., & Güleç, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237465 · Cited by 7
Zheng, X., Zhong, L., Zhou, T., Zhao, F., & Chen, B. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0043 · Cited by 4
Minakata, M., Ito, M., Kishi, T., Okazaki‐Hada, M., Masaki, Y., Nakamura, T., Kousaka, K., Kasahara, T., Kudo, T., Nishihara, E., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0109 · Cited by 6
Wiseman, S. M., Memarnejadian, A., Boyce, G. K., Nguyen, A., WALKER, B. A. M., Holmes, D. T., Welch, I. D., Mazzuca, D. M., & Toleikis, P. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262345 · Cited by 5
“Thus, compared to individuals with an intact thyroid gland, some people receiving LT4 monotherapy will have lower circulating free T3 to T4 ratios, and some may not even maintain normal serum T3 or T4 levels [1,13].”
BackgroundCancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study
McVicker, L., Cardwell, C. R., McIntosh, S., & McMenamin, Ú. C. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06674-5 · Cited by 6
“1 3 a patient has serum TSH levels within an acceptable range [55, 56].”
BackgroundMehran, L., Amouzegar, A., Foroutan, S. M., Masoumi, S., Tohidi, M., Abdi, H., Aghaei, A., Saghafinia, A. E., & Azizi, F. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01434-y · Cited by 6
“Approximately 10% lower serum T3 levels in LT4-treated patients compared to euthyroid individuals with similar serum TSH values have been reported previously, leading to the skewed T3:T4 ratio toward an increase of T4, while serum T3 levels are normal to low [4–7].”
BackgroundLevothyroxine personalized treatment: is it still a dream?
Cappelli, C., Gatta, E., & Ippolito, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1334292 · Cited by 7
Liquid liothyronine to obtain target TSH in differentiated thyroid cancer patients
Trimboli, P., Centanni, M., & Virili, C. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0040 · Cited by 4
Pharmacodynamic and Therapeutic Actions of Levothyroxine
Hennessey, J. V. (2021) · 70 Years of Levothyroxine · doi:10.1007/978-3-030-63277-9_3 · Cited by 4
Free triiodothyronine/free thyroxine ratio in children with congenital hypothyroidism
Sydlik, C., Dubinski, I., Bechtold, S. M., & Schmidt, H. (2022) · Endocrine Connections · doi:10.1530/ec-22-0032 · Cited by 3
Metadata
- Authors
- Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R.
- Affiliations
- University of Catania (IT)
- Corresponding author
- Gullo, Damiano
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-01
- Volume
- 6
- Issue
- 8
- Pages
- e22552
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3148220
- OpenAlex
- W2163820892
- Cited by
- 307
- References
- 32
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 20 · 2023: 26 · 2022: 27 · 2021: 25 · 2020: 31 · 2019: 30 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 18 · 2014: 12 · 2013: 9 · 2012: 10
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Università di Catania
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- levothyroxine monotherapy, athyreosis, hypothyroidism, free triiodothyronine, free thyroxine, T3/T4 ratio, thyroid-stimulating hormone, euthyroidism
- MeSH terms
- Humans, Hypothyroidism, Immunoenzyme Techniques, Retrospective Studies, Thyroid Hormones, Thyrotropin, Thyroxine, Case-Control Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.